@article{85421, keywords = {Animals, Macaca mulatta, Female, Male, Virus Internalization, Neutralization Tests, Receptors, CCR5, HIV-1, AIDS Vaccines, Antibodies, Neutralizing, Antigens, CD4, CCR5 Receptor Antagonists, Dependovirus, Genetic Therapy, HIV Antibodies, HIV-2, Immunoglobulins, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus}, author = {Matthew Gardner and Lisa Kattenhorn and Hema Kondur and von Markus Schaewen and Tatyana Dorfman and Jessica Chiang and Kevin Haworth and Julie Decker and Michael Alpert and Charles Bailey and Ernest Neale and Christoph Fellinger and Vinita Joshi and Sebastian Fuchs and Jose Martinez-Navio and Brian Quinlan and Annie Yao and Hugo Mouquet and Jason Gorman and Baoshan Zhang and Pascal Poignard and Michel Nussenzweig and Dennis Burton and Peter Kwong and Michael Piatak and Jeffrey Lifson and Guangping Gao and Ronald Desrosiers and David Evans and Beatrice Hahn and Alexander Ploss and Paula Cannon and Michael Seaman and Michael Farzan}, title = {AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.}, abstract = {

Long-term in vivo expression of a broad and potent entry inhibitor could circumvent the need for a conventional vaccine for HIV-1. Adeno-associated virus (AAV) vectors can stably express HIV-1 broadly neutralizing antibodies (bNAbs). However, even the best bNAbs neutralize 10-50\% of HIV-1 isolates inefficiently (80\% inhibitory concentration (IC80)\ \>\ 5\ μg\ ml(-1)), suggesting that high concentrations of these antibodies would be necessary to achieve general protection. Here we show that eCD4-Ig, a fusion of CD4-Ig with a small CCR5-mimetic sulfopeptide, binds avidly and cooperatively to the HIV-1 envelope glycoprotein (Env) and is more potent than the best bNAbs (geometric mean half-maximum inhibitory concentration (IC50)\ 

}, year = {2015}, journal = {Nature}, volume = {519}, pages = {87-91}, month = {03/2015}, issn = {1476-4687}, doi = {10.1038/nature14264}, language = {eng}, }